Orion OYJ (OTCMKTS:ORINY) Shares Up 0% - Still a Buy?

Key Points

• Orion OYJ's stock traded flat at $39.85, with a significant decrease in trading volume, down 55% from the average.
• The company reported a net margin of 22.61% and earnings per share (EPS) of $0.33 for the previous quarter, with forecasts estimating an EPS of 1.18 for the current year.
• Orion OYJ focuses on pharmaceutical development for both human and veterinary medicines, offering a range of products including treatments for cancer, pain, and Parkinson's disease.

Shares of Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) rose 0% during mid-day trading on Tuesday . The stock traded as high as $39.85 and last traded at $39.85. Approximately 253 shares were traded during trading, a decline of 55% from the average daily volume of 565 shares. The stock had previously closed at $39.84.

Orion OYJ Stock Performance

The firm has a 50 day simple moving average of $38.76 and a 200-day simple moving average of $33.09. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.86 and a quick ratio of 1.05. The company has a market cap of $11.34 billion, a price-to-earnings ratio of 27.32 and a beta of 0.10.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last posted its earnings results on Friday, July 18th. The company reported $0.33 earnings per share (EPS) for the quarter. The company had revenue of $472.57 million during the quarter. Orion OYJ had a return on equity of 38.68% and a net margin of 22.61%. As a group, analysts predict that Orion OYJ Unsponsored ADR will post 1.18 EPS for the current fiscal year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.